{
    "nct_id": "NCT01018875",
    "title": "A Randomized, Double-Blind, Active- and Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABT-288 in Subjects With Mild-to-Moderate Alzheimer's Disease",
    "status": "COMPLETED",
    "last_update_time": "2018-06-01",
    "description_brief": "Efficacy and safety study of ABT-288 in adults with mild-to-moderate Alzheimer's disease.",
    "description_detailed": "N/A",
    "phase": [
        "PHASE2"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "TREATMENT",
    "results": null,
    "target_category": "Cognitive enhancer",
    "drug": [
        "ABT-288 (histamine H3 receptor antagonist)"
    ],
    "placebo": [
        "placebo"
    ],
    "explanation_target": [
        "Reason: The investigational agent ABT-288 is a selective histamine H3 receptor antagonist developed as a procognitive (symptomatic cognitive-enhancing) small molecule rather than a biologic or an anti-amyloid/tau disease-modifying agent. \ue200cite\ue202turn0search5\ue202turn0search8\ue201",
        "Act: The trial title and description match a randomized, double-blind, placebo- and active-controlled (donepezil as active control) 12-week study in mild-to-moderate Alzheimer\u2019s disease; the study was stopped for futility and ABT-288 did not demonstrate symptomatic cognitive benefit. \ue200cite\ue202turn0search5\ue202turn0search0\ue201",
        "Act (drug info): Phase 1 and other clinical reports describe ABT-288 pharmacology and tolerability as an H3 antagonist with procognitive intent (clinical testing in elderly/AD and in cognitive impairment in schizophrenia). \ue200cite\ue202turn0search2\ue202turn0search3\ue201",
        "Reflect: Given the mechanism (H3 receptor antagonism aiming to enhance cognition) and absence of an anti-amyloid/tau mechanism, the trial fits the 'Cognitive enhancer' category (symptomatic cognitive improvement), not 'disease-targeted small molecule' or 'disease-targeted biologic'. The classification is consistent with the cited publications above. \ue200cite\ue202turn0search5\ue202turn0search0\ue201",
        "Web-search results used: PubMed / Journal of Alzheimer\u2019s Disease reports of the randomized ABT-288 AD study and trial outcome; phase 1 PK/safety reports; schizophrenia cognitive trials \u2014 sources: Journal of Alzheimer\u2019s Disease (IOS Press) summary and PubMed abstracts/full-text (turn0search5, turn0search0, turn0search2, turn0search3, turn0search8). \ue200cite\ue202turn0search5\ue202turn0search0\ue202turn0search2\ue202turn0search3\ue202turn0search8\ue201"
    ],
    "agent_type": "D) Neurotransmitter Receptors",
    "explanation_agent": [
        "Reason: The investigational agent ABT-288 is a selective histamine H3 receptor antagonist (an antagonist of a G-protein coupled neurotransmitter receptor) developed as a procognitive/symptomatic cognitive-enhancing small molecule rather than an anti-amyloid or anti-tau disease-modifying therapy. \ue200cite\ue202turn0search1\ue202turn0search2\ue201",
        "Act: The trial described (randomized, double-blind, placebo- and active-controlled in mild-to-moderate AD) tested ABT-288 for symptomatic cognitive enhancement; the mechanism is H3 receptor antagonism which modulates central neurotransmitter release (e.g., acetylcholine, dopamine) \u2014 this maps to the CADRO category for neurotransmitter receptors. The clinical AD study was stopped for futility (ABT-288 showed no cognitive benefit vs placebo; donepezil showed improvement). \ue200cite\ue202turn0search3\ue202turn0search0\ue201",
        "Reflect: Given the explicit H3 receptor target (a histaminergic neurotransmitter receptor) and absence of amyloid/tau/ApoE/vascular/inflammatory primary mechanisms, the most specific CADRO match is D) Neurotransmitter Receptors. There is no indication this was a multi-target or non-therapeutic diagnostic trial. Phase 1 and other clinical reports support the H3 antagonist pharmacology and procognitive intent. \ue200cite\ue202turn0search2\ue202turn0search1\ue201",
        "Web search results (key sources used):",
        "- PubMed summary of the randomized AD study reporting ABT-288 (H3 antagonist) in mild-to-moderate Alzheimer's dementia; study terminated for futility. \ue200cite\ue202turn0search0\ue201",
        "- Journal of Alzheimer's Disease (full/IOS Press) article reporting the randomized, placebo- and active-controlled ABT-288 study and negative efficacy. \ue200cite\ue202turn0search3\ue201",
        "- Pharmacology paper describing ABT-288 as a potent, selective histamine H3 receptor antagonist with procognitive effects in preclinical models. \ue200cite\ue202turn0search1\ue201",
        "- Phase 1 safety/tolerability and pharmacokinetics report in young and elderly subjects (supports dose selection and H3 mechanism). \ue200cite\ue202turn0search2\ue201",
        "Output: D) Neurotransmitter Receptors \u2014 ABT-288 is an H3 histamine receptor antagonist (a neurotransmitter receptor target) and the trial tested symptomatic cognitive enhancement rather than disease-modifying pathology-directed therapy."
    ]
}